MTOR and B-cell non-Hodgkin lymphoma: The results of this current study demonstrate that the in vivo apoptotic effects of rapalog and active site mTOR inhibitors are caused by the downregulation of VEGF protein expression and the subsequent inhibition of angiogenesis in a B-cell lymphoma xenograft.